Viral Pathogenesis Laboratory and Clinical Trials Core, Vaccine Research Center, National Institutes of Allergy and Infectious Diseases, National Institutes of Health, US Department of Health and Human Services, 40 Convent Drive, Bethesda, MD 20892, United States.
J Immunol Methods. 2010 Oct 31;362(1-2):180-4. doi: 10.1016/j.jim.2010.08.005. Epub 2010 Aug 19.
Respiratory syncytial virus (RSV) is an important cause of respiratory infection in people of all ages, and is the leading cause of hospitalization in infants. Although commercially available monoclonal antibody is available for passive prophylaxis of neonates at risk of severe disease, there is no available vaccine to prevent RSV. Measurement of neutralizing activity will be a key endpoint for vaccine evaluation. Assessment of neutralizing antibody against RSV has been limited to traditional plaque reduction, which is time-consuming and inherently operator dependent and highly variable. Here, we describe a flow cytometry-based RSV-specific neutralization assay which is more rapid than traditional methods, highly sensitive and highly reproducible.
呼吸道合胞病毒（RSV）是全年龄段人群呼吸道感染的重要病因，也是导致婴儿住院的首要原因。虽然已有市售的单克隆抗体可用于重症疾病风险新生儿的被动预防，但目前尚无 RSV 疫苗。中和活性的测量将是疫苗评估的关键终点。对 RSV 中和抗体的评估一直受到传统蚀斑减少法的限制，该方法耗时且固有地依赖于操作人员，变异性大。在此，我们描述了一种基于流式细胞术的 RSV 特异性中和测定法，该方法比传统方法更快，灵敏度更高且重现性更好。
